Compare Mesoblast Limited (MESO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Waste Management, Inc. — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Waste Management, Inc. trades at $233.17 (market cap $96.00B). The key difference: Waste Management, Inc. is far larger — about 44.2× Mesoblast Limited's market cap, and Waste Management, Inc. pays a 1.48% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WM | |
|---|---|---|
Market Cap | $2.17B | $96.00B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $246.51 |
52-Week Low | $12.88 | $196.77 |
Enterprise Value | $2.17B | $118.73B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
WM (Waste Management) trades at $233.18, down 2.56% on the day, but remains near its 52-week high of $248.13. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $25.20 billion in 2025 and a robust 10.99% net income margin. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 results missed. Analyst sentiment is positive with a consensus buy rating and $263.57 price target, supported by a reliable dividend and strong cash flow from operations of $6.04 billion.
Outlook: WM's dominant market position, pricing power, and renewable energy initiatives support long-term growth, but high debt levels and competitive pressures pose risks. The stock offers value for income and growth investors, with potential upside to analyst targets if execution remains solid amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
